朗玛信息(300288) - 2024 Q4 - 年度业绩预告

Financial Performance - The company expects a net loss of between 505.13 million yuan and 525.13 million yuan for the year 2024, compared to a profit of 77.46 million yuan in the same period last year, representing a decline of 752.14% to 777.96%[2]. - Without considering the goodwill impairment, the estimated net profit attributable to shareholders is projected to be between 45 million yuan and 65 million yuan, reflecting a decline of 41.90% to 16.08% compared to the previous year[6]. - Non-recurring gains and losses are expected to impact the current net profit by approximately 1.5 million yuan, down from 3.31 million yuan in the same period last year[7]. Goodwill Impairment - The anticipated impairment of goodwill is approximately 570.13 million yuan due to a significant decline in revenue from the acquired subsidiary, Guangzhou Qisheng Information Technology Co., Ltd.[5]. - The company has sufficient cash flow and is not affected by the goodwill impairment, indicating normal operations[8]. Business Strategy - The company's main business revenue has decreased due to changes in market demand and the allocation of quality medical information content for internal AI training rather than for sales[6]. - The company is actively adjusting its development strategy by controlling costs, optimizing business structure, and focusing on research and development in the medical AI field[6]. Financial Reporting - The preliminary financial data is subject to audit and will be detailed in the annual report scheduled for April 25, 2025[10].